For the Inventor, By the Inventor

Enter assignee name

La Jolla, CA, United States of America

Inhibrx, Inc.

Calculating rank

USPTO Granted Patents = 30

CIPO Patents = 16

EPO Patents = 6

Trademarks = 2

Forward Citations = 141

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

John C Timmer (30 out of 44 patents)

Brendan P Eckelman (30 out of 48 patents)

Quinn L Deveraux (24 out of 39 patents)

4. Kyle S Jones (14 out of 15 patents)

5. Amir S Razai (10 out of 12 patents)

6. Peter L Nguy (9 out of 9 patents)

7. Abrahim Hussain (8 out of 10 patents)

8. Katelyn M Willis (7 out of 14 patents)

9. Grant B Guenther (7 out of 7 patents)

10. Rajay A Pandit (5 out of 11 patents)

11. Andrew Hollands (5 out of 7 patents)

12. Bryan Becklund (4 out of 5 patents)

13. William Crago (4 out of 7 patents)

14. Angelica N Sanabria (3 out of 10 patents)

15. Florian Sulzmaier (3 out of 4 patents)

Core Competencies:

OX40-binding Polypeptides

DR5-binding Fusion Proteins

Single Domain Antibodies

CD123-binding Polypeptides

Serpin Fusion Polypeptides

Multispecific Constructs

GITR-binding Fusion Proteins

Type III Secretion System

30 patents: Sort by Forward Citations

1. 12012459 - OX40-binding polypeptides and uses thereof (2024-06-18),

2. 11976126 - Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells (2024-05-07),

3. 11965017 - Serpin fusion polypeptides and methods of use thereof (2024-04-23),

4. 11945869 - PD-1 single domain antibodies and therapeutic compositions thereof (2024-04-02),

5. 11919963 - CD123-binding polypeptides and uses thereof (2024-03-05),

6. 11866507 - Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same (2024-01-09),

7. 11827691 - Serpin fusion polypeptides and methods of use thereof (2023-11-28),

8. 11566078 - PDL1-binding proteins (2023-01-31),

9. 11560428 - CD33-binding polypeptides and uses thereof (2023-01-24),

10. 11434297 - CD123-binding polypeptides and uses thereof (2022-09-06),

11. 11208485 - PD-1 single domain antibodies and therapeutic compositions thereof (2021-12-28),

12. 11117973 - Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms (2021-09-14),

13. 11117972 - Multivalent and multispecific OX40-binding fusion proteins (2021-09-14),

14. 11046752 - Serpin fusion polypeptides and methods of use thereof (2021-06-29),

15. 10844129 - Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids (2020-11-24),

Company Overview

Inhibrx, Inc. is a biotechnology company based in La Jolla, California, focused on developing innovative therapies for patients with serious diseases. The company specializes in the design and development of biologic therapeutics, particularly in the fields of oncology and autoimmune disorders. Inhibrx leverages advanced protein engineering and drug discovery technologies to create novel treatments that aim to improve patient outcomes and address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

30 Patents

#21 in La Jolla, CA

#2,686 in California

#11,255 in US

#21,924 in the World

La Jolla, CA, United States of America

Inhibrx, Inc.

Forward Citations = 141

23 inventors:

John C Timmer (30 out of 44 patents)

Brendan P Eckelman (30 out of 48 patents)

Quinn L Deveraux (24 out of 39 patents)

4. Kyle S Jones (14 out of 15 patents)

5. Amir S Razai (10 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Inhibrx, Inc.. Retrieved from https://idiyas.com/company/inhibrx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…